Login / Signup

Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice.

Kuo-Tung HungShih-Cheng YangCheng-Kun WuHsing-Ming WangChih-Chien YaoChih-Ming LiangWei-Chen TaiKeng-Liang WuYuan-Hung KuoChen-Hsiang LeeSeng-Kee Chuah
Published in: Infection and drug resistance (2021)
The eradication rates between esomeprazole and lansoprazole-based non-bismuth concomitant quadruple therapy for first-line H. pylori treatment were similar in this study. Both could achieve a > 90% report card in the PP analysis.
Keyphrases
  • helicobacter pylori
  • helicobacter pylori infection
  • clinical practice
  • oxide nanoparticles